Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
1993 pubmed 87 citations

Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6.

Peñalva. A A; Pombo. M M; Carballo. A A; Barreiro. J J; Casanueva. F F FF; Dieguez. C C

Key Findings

  • A single IV dose of 1 µg/kg GHRP‑6 sharply raises plasma GH in both adults and pre‑pubertal children.
  • The GH response is not affected by sex, age, or menstrual cycle stage.
  • Pretreatment with the alpha‑1 blocker prazosin further amplifies the GH increase, whereas propranolol (beta‑blocker) and clonidine (alpha‑2 agonist) have no effect.

Practical Outcomes

  • For biohackers, GHRP‑6 can be used at the studied dose without worrying about gender or age differences. Adding an alpha‑1 blocker like prazosin could boost the GH spike, but it also adds extra pharmacological risk, so it’s not a necessary part of a basic protocol. Beta‑blockers or alpha‑2 agents won’t change the outcome.

Summary

GHRP‑6 reliably spikes growth hormone in adults and kids, and it works the same way in men, women, and across the menstrual cycle. Blocking alpha‑1 receptors with prazosin makes the GH surge even bigger, while beta‑blockers (propranolol) and alpha‑2 agonists (clonidine) don’t change the response.

Abstract

His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6) is a synthetic compound that releases GH in a dose-related and specific manner in several species including man. To further characterize the effects of GHRP-6 on GH secretion in normal human subjects, we assessed plasma GH levels following GHRP-6 administration in normal male adult subjects, normal female adult subjects at different stages of their menstrual cycle and in normal prepubertal male and female children. We also studied the influence of adrenergic pathways on GHRP-6 induced GH secretion in normal adult male subjects. In a group of eight volunteers the following tests were carried out: GHRP-6 alone (1 microgram/kg i.v. at 0 minutes); propranolol (40 mg p.o. at -30 minutes) plus GHRP-6; and prazosin (3 mg p.o. at -120 minutes) plus GHRP-6. Another group of eight volunteers were studied with GHRP-6 as above; clonidine alone (300 mg p.o. at -60 minutes); and clonidine plus GHRP-6. A group of nine women were studied with 1 microgram/kg i.v. of GHRP-6 at 0 minutes, at different stages of their menstrual cycle. Finally, 12 children were studied with GHRP-6 using the same dose and methods as above. Twenty-five normal adult subjects (16 male and nine female) and 12 normal prepubertal children (six male and six female) wer studied after giving informed consent. Plasma GH levels were measured by radioimmunoassay. No differences in GH responses to GHRP-6 were found between children and normal adult male or female subjects at different stages of their menstrual cycle. Administration of propranolol and clonidine did not modify the GH responses to GHRP-6 in male adults. In contrast, prazosin administration induced an increase in plasma GH levels that was statistically different from that of GHRP-6 alone (. < 0.05 between area under curve). GHRP-6 exerts a potent stimulatory effect on GH secretion in adults and children. Its effects, at least at the dose studied, are independent of sex and age. Noradrenergic pathways through alpha 2 adrenergic receptors are unlikely to influence this response.

Study Information

Provider

pubmed

Year

1993

Date

1993-01-01T00:00:00.000Z

DOI

10.1111/j.1365-2265.1993.tb00977.x

Citations

87

References

45